Brunel University Research Archive (BURA) >
Special Research Institutes >
Health Economics Research Group (HERG) >

Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/4586

Title: Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen
Authors: Lindgren, P
Buxton, MJ
Kahan, T
Poulter, NR
Dahlof, B
Sever, PS
Wedel, H
Jönsson, B
Keywords: Hypertension
Primary prevention
Amlodipine
Atenolol
Cost-effectiveness
Publication Date: 2008
Publisher: British Medical Journals Publishing Group Ltd & British Cardiovascular Society
Citation: Heart 94: e4, 2008
Abstract: Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.Setting: Primary care.Patients: Patients with moderate hypertension and three or more additional risk factors.Interventions: Amlodipine 5-10 mg with perindopril 4 8 mg added as needed or atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as neededMain outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.Results: In the UK, the cost to avoid one cardiovascular event or procedure would be (sic)18 965, and the cost to gain one quality-adjusted life-year would be (sic)21 875. The corresponding figures for Sweden were (sic)13 210 and (sic) 856.Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare's Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol- based regimen in the population studied.
Description: Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society All rights reserved.
Sponsorship: The study was supported by the principal funding source, Pfizer, New York, USA
URI: http://heart.bmj.com/content/94/2/e4.full
http://bura.brunel.ac.uk/handle/2438/4586
DOI: http://dx.doi.org/10.1136/hrt.2007.127217
ISSN: 1355-6037
Appears in Collections:Health Economics Research Group (HERG)

Files in This Item:

File Description SizeFormat
Fulltext.pdf108.91 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.